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Abstract  
 
Purpose:  
 
Worldwide, the incidence of thick melanoma has not declined, and the nodular melanoma 
(NM) subtype accounts for nearly 40% of newly-diagnosed thick melanoma. To assess 
differences between patients with thin (≤2.00 mm) and thick (≥2.01 mm) nodular 
melanoma, we evaluated factors such as demographics, melanoma detection patterns, 
tumor visibility, and physician screening for NM alone and compared clinical 
presentation and anatomic location of NM with superficial spreading melanoma (SSM). 
 
Methods 
 
We utilized data from a large population-based study of Queensland (Australia) residents 
diagnosed with melanoma. Queensland residents aged 20 to 75 years with histologically 
confirmed first primary invasive cutaneous melanoma were eligible for the study, and all 
questionnaires were conducted by telephone (response rate 77.9%).   
 
Results 
 
During this four-year period, 369 patients with nodular melanoma were interviewed, of 
whom 56.7% were diagnosed with tumors ≤ 2.00 mm. Men, older individuals, and those 
who had not been screened by a physician in the past three years were more likely to 
have nodular tumors of greater thickness.  Thickest nodular melanoma (4 mm+) was also 
most common in persons who had not been screened by a doctor within the past three 
years (OR 3.75; 95% CI 1.47-9.59).  Forty-six percent of patients with thin nodular 
melanoma (≤ 2.00 mm) reported a change in color, compared with 64% of patients with 
thin SSM and 26% of patients with thick nodular melanoma (>2.00 mm). 
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Conclusion 
 
Awareness of factors related to earlier detection of potentially fatal nodular melanomas, 
including the benefits of a physician examination, should be useful in enhancing public 
and professional education strategies.  Particular awareness of clinical warning signs 
associated with thin nodular melanoma should allow for more prompt diagnosis and 
treatment of this subtype.  
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Introduction 
 
  
Melanoma survival is strongly associated with thickness of the primary lesion. 1 
The median tumor thickness of cutaneous melanoma has decreased significantly over the 
past three decades as a result of earlier detection that has coincided with sharply rising 
incidence, particularly of thin melanoma, in Europe, Australia, and the United States. 2-4   
Almost 70% of these melanomas are of the superficial spreading histological subtype, 
and early detection is likely related to public and professional awareness of the ABCDE 
early melanoma warning signs. 5 
 
Despite the decrease in median tumor thickness, the incidence of thick melanoma 
has not declined. 6-8 The nodular melanoma (NM) subtype accounts for a substantial 
fraction of newly-diagnosed thick primary tumors with known histology in both Australia 
and the United States. 9-12 For example, in the US SEER registry, NM comprises only 
10% of all invasive melanoma, but nearly 50% of all melanoma greater than 2.0 mm, a 
thickness cut-off point frequently used to distinguish thin from thick melanoma. 10 In 
Queensland, NM comprises 8% of all invasive melanoma but 38% of melanoma thicker 
than 2.0 mm. 12 Similarly, a Swedish report found nodular melanoma to comprise 9% of 
all melanoma and 40% of all lesions greater than 2.0 mm, 13 and in Italy, NM makes up 
65% of > 2mm compared with less than 10% of superficial spreading melanoma (SSM). 
14 In Italy, from 1985-87 to 1995-97, there was a significant shift toward thinner 
melanoma, but most recent data showed that the nodular subtype and advanced age were 
the only variables significantly associated with thick melanoma. 2 
 
Nodular melanoma is commonly believed to be a rapidly growing subtype that 
eludes early detection because of its greater biological ‘aggressiveness’. 11 New 
approaches to screening and education are required to reduce the incidence of thick 
melanoma. However, there are few reports that have characterized factors associated with 
differences between thin and thick nodular melanomas, and the diagnostic features of 
early NM have yet to be clearly defined. 11 Therefore, we aimed to: (1) evaluate social 
demographics, discovery patterns, and phenotypic factors that differ between thin and 
thick NM; and (2) determine if there were differences in clinical presentation between 
patients with thin NM, thick NM, thin SSM, and thick SSM.  Awareness of factors 
related to earlier detection of the most commonly fatal melanoma subtype should be 
useful in enhancing new public and professional education strategies and could help to 
elucidate the interactions of tumor biology and clinical presentation of this subtype.  
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Methods 
 
We utilized data from a large population-based study of Queensland (Australia) 
residents diagnosed with melanoma, for which the fieldwork methodology has been 
previously described in detail.  15 Briefly, Queensland residents aged 20 to 75 years with 
histologically confirmed first primary invasive cutaneous melanoma between January 1, 
2000 and December 31, 2003 were eligible for the study. For sampling and cost-
efficiency, a random 60% sample of participants with melanoma <0.75 mm were 
selected, while a census of those with greater tumor thickness were included.  Patients 
with metastatic disease, a previous melanoma, or acral lentiginous or mucosal melanoma 
were excluded. After permission was obtained from the treating physician, patients were 
invited by letter to participate in a telephone survey. Ethical clearance for the original 
fieldwork was obtained from the University of Queensland Ethical Review Committee, 
while additional approval to conduct this subsequent analysis was obtained from Boston 
University.  
 
 Of 4839 eligible patients, physician consent was obtained for 4510 (93.2%); 3887 
patients (80.3% of the total eligible sample) agreed to participate, and 3772 (77.9%) 
completed an interview. The median time between diagnosis and interview was 5 months 
(range, 1-26 months). Five people died prior to being interviewed. Of 542 eligible 
patients diagnosed with nodular melanoma, physician consent was obtained for 512 
(94.5%), 421 patients (77.7% of the total eligible sample) agreed to participate, and 369 
(68.1%) completed an interview.  
 
Data were collected from respondents via telephone by trained interviewers using 
a computer-assisted telephone interview system. Interviewers were blinded to specific 
tumor thickness and to histologic subtypes. Among other items, the interview collected 
information on sociodemographics (age in 10-year age groups, gender, and highest 
educational achievement categorized into primary, grades 7-10, or grade >11), anatomic 
site of melanoma, whether the melanoma was first noticed through a deliberate skin 
check, or noticed accidentally by the patient, partner, or doctor who first noticed the 
melanoma (self, partner, or doctor), and performance of self-screening in previous three 
years.  Respondents were surveyed regarding physician screening (defined as whether a 
doctor deliberately checked all or nearly all of case’s body for the early signs of skin 
cancer during the last 3 years), self-reported ‘moliness’ (according to diagrams 
illustrating many/some vs. few/none), visibility of lesion (not visible vs. visible), and skin 
reaction to summer sun (always/usually burns vs. sometimes/never burns). Lesions were 
determined to be nonvisible to the patient if they were on the scalp, back, buttocks, back 
of the neck, ears and shoulders, back of the legs, and soles of the feet. All other 
melanomas were considered to be on visible sites of the body.  
 
Respondents were asked ‘on the date you first believed something was wrong, 
what was it about the spot that made you or someone else believe something might be 
wrong?’ Choices included: change in color, change in size, irregular shape, irritation/itch, 
lumpy/raised appearance, different from other spots, bleeding/weeping, dry/scaly, blister-
like, pain, pigmentation(brown, black, red/pink, pale/no color, gray/blue). Respondents 
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were also asked if the lesion ‘just appeared’.  Patients whose melanoma was detected by a 
physician were not asked this series of questions. 
 
Further detail on the survey questions have been provided earlier.15-16   The test-
retest reliability of the survey was examined by re-interviewing 186 patients within 1 to 3 
months of the first interview. Agreement ranged from 76.6% for one of the symptoms to 
93% for skin self-examination. 17 
 
Interview data were combined with pathology data in the Queensland Cancer 
Registry, including melanoma thickness, histologic type, anatomic site of lesion 
(categorized as scalp and neck, upper extremities, lower extremities, back of trunk, and 
front on trunk), and level of invasion.  
 
Statistical Analysis 
 
We conducted bivariate and multivariate analyses of the associations between 
melanoma thickness and selected variables for the 369 respondents with histologicially-
confirmed nodular melanomas. In all analyses, the proportion of thin melanoma was 
weighted to account for the undersampling (60%) of melanomas <0.75 mm in this study, 
in contrast to the inclusion of all thicker (≥0.75 mm) tumors.  
 
Melanoma thickness was first treated as a continuous variable and modeled on a 
log scale. Associations are reported as ratios of the geometric means compared to the 
reference category with 95% confidence intervals. We report unadjusted bivariate 
estimates and multivariate associations with adjusted estimates for all of the explanatory 
variables shown in Table 1. Likelihood ratio (chi-square) statistics were used to assess the 
significance of variables from the multivariate models. Results are expressed as the 
exponential of the relevant parameter estimate from the model, and reflect the ratio of the 
geometric mean relative to the baseline category. 
 
Because we were interested in understanding more about the factors related to the 
thickest and thinnest NM, we used multinomial regression models to assess the 
association between the same set of variables against tumor size (>4 mm, 1-4 mm, <1 
mm) to produce odds ratios and 95% confidence intervals.  This latter analysis was 
adjusted for age and sex only because of the limited number of tumors in the three 
separate tumor groups.  
 
For questions regarding clinical features and anatomic sites, we calculated 
percentages reporting each feature and compared responses for patients with thin (≤2.0 
mm) NM, thick (>2.0 mm) NM, thin (≤2.0 mm) SSM and thick (>2.0 mm) SSM. We 
specifically compared thin NM with thick NM, thin NM with thin SSM, and thick NM 
with thick SSM.  For these analyses, we included only those melanomas detected by 
someone other than a physician. Significance across all three groups was assessed using 
chi-squared statistic with 2 degrees of freedom, and 95% confidence intervals calculated 
for each percentage estimate.  
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Results 
 
Of the 369 respondents with NM, 60% were men. The median age of diagnosis 
was 57 years (range 20-76 years), and 66% were 50 years of age and older. More than 
56% had an educational level of grade 11 and above. About half (52%) reported that their 
skin always or usually burned upon first reaction to the summer sun. The median tumor 
thickness was 1.90 mm, ranging from 0.40 mm to 9.30 mm. Nodular melanoma was 
characterized in accordance with 2002 AJCC/UICC melanoma staging T classifications: 
≤1 mm (T1, 22.2%), 1.01-2.0 mm (T2, 34.5%), 2.01-4.0 mm (T3, 30.6% ), and >4.0 mm 
(T4, 12.7%).  
 
Sixty-one percent of NM was self-detected, 27% detected by a partner, but only 
11% detected by a physician. Only 53% of NMs were visible to the patient. Twenty-eight 
percent of patients had received a deliberate physician screen on all or nearly all of the 
whole body for early signs of skin cancer in the past three years, but only 15% of 
participants had performed a skin self-examination in the prior three years. Forty-two 
percent of patients reported that they had “many/some” moles.  
 
For NM, men and older respondents were more likely to have tumors of greater 
thickness, after adjustment for all the other variables shown in Table 1.  Thick NMs were 
also more likely in respondents who had not been screened by a physician in the past 
three years, and among those whose melanoma was on a visible part of their body. A 
non-significant trend toward thick NM was found among those who discovered their own 
lesion compared with a physician-detected NM.  Seventy percent of visible lesions were 
first noticed by the individual compared with 54% of non-visible lesions, and partners 
were more likely to detect non-visible lesions (31% v. 21%) (significant association 
between visibility and who first noticed the lesion, chis-sq=9.55, df=2, p=0.008).  
 
Results from the multinomial model (adjusted for age and sex) demonstrated 
significant associations between NM thickness and age group, having had a clinical skin 
examination in the last three years, whether the lesion was on a visible part of the body, 
who first noticed the lesion, and self-reported ‘moliness’ (Table 2). Specific analysis of 
NM of the extreme thickness categories (T1 and T4) revealed that respondents aged 60-
75 years were nearly three times more likely to have a T4 NM than a T1 NM, compared 
with respondents aged 40-59 years, (OR 2.94; 95% CI 1.33-6.47).  Compared with 
respondents who had a clinical skin examination (CSE) in the last three years, 
respondents who did not have a CSE were nearly four times more likely to have a T4 NM 
than a T1 NM(OR 3.75; 95% CI 1.47-9.59). In comparison with respondents whose NM 
was detected by a doctor, those with self-detected melanoma were nearly five times more 
likely to be T4 than T1 (OR 4.86; 95% CI 1.21-19.51).  
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Clinical features of nodular melanoma 
 
Thin NM vs. Thick NM 
 
Patients with thin NM were nearly twice as likely as patients with thick NM to 
report a change in color (46.2% vs. 25.8%), five times more likely to observe an irregular 
shape, and far more likely to report brown pigmentation (47.4% v. 27.2%). Patients with 
thick NM more commonly reported a lumpy/raised appearance, bleeding/weeping, 
blister-like, red/pink pigmentation, and paleness/no color. The scalp and neck was more 
commonly a site for thick NM and the back of the trunk was more frequently a site of 
thin NM. However, for many other clinical features, such as change in size, irritation or 
onset of itch, the lesion being 'different from other spots’, or having 'just appeared'’(1.4% 
of thin NM patients and 4.6% of thick NM patients)(Table 3), there were few differences 
between thin NM and thick NM. 
 
Thin SSM vs. Thin NM 
 
Patients with thin SSM were more likely than patients with a thin NM to report a 
change in color (64.2% vs. 46.2%) and brown pigmentation (63.1% vs.47.4%). 
Bleeding/crusting/weeping and a lumpy/raised appearance were more common in thin 
NM than thin SSM. However, for many other clinical features, such as change in size, 
shape, ‘different from other spots’, lesion 'just appearing’, and for body site location, 
there were few differences between thin NM and thin SSM.  
 
In general, there were few differences in clinical features between patients with 
thick NM and thick SSM in the proportion of respondents, although the former more 
commonly reported bleeding/crusting/weeping, blisters and red/pink pigmentation.   
 
Discussion 
 
In the United States, Australia, Italy, and elsewhere, the NM subtype accounts for 
a disproportionate fraction of thick cutaneous disease. 10-11,14  As melanoma thickness is 
strongly related to survival, gaining an understanding of this subtype is likely to be 
helpful in reducing melanoma mortality. 
 
Four major findings emerge from this analysis of the Queensland population-
based cancer registry. There have been few reports of the presentation of thin NM -
herein, 57% of nodular melanomas were diagnosed ≤2.0 mm. This report coupled with a 
similar finding from the US SEER registry 10 augurs well for identifying a significant 
subset of NM that can be detected relatively early.  Second, well-established warning 
signs, known to be common for SSM, such as change in color and brown pigment, were 
relatively common among patients diagnosed with thin NM. In fact, nearly half of all 
patients with thin NM reported a change in color. Third, social demographics known to 
be related to more deeply invasive melanoma such as older age and male sex were also 
associated with thick NM.  Finally, the absence of a physician skin examination in the 
three years before diagnosis was also associated with thick NM.  
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Alerting the public and professionals alike to the warning signs of melanoma 
while advocating early and prompt referrals for suspect lesions has been the hallmark for 
education on early detection. Due to concerted early detection campaigns,  progress in 
Australia and the US has been made in reducing the median tumor thickness of SSM, 
although the proportion of thick SSMs has remained virtually the same.  10,12 Less than 
7% and 5% of all SSMs diagnosed in the US and Queensland respectively are greater 
than 2 mm compared with similar rates in the 1980s. However,  in both US and 
Queensland population-based cancer registries, NM is about one-sixth as common as 
SSM but 6 times more likely to result in thick melanoma. 10,12 Thus, enhancing earlier 
detection of nodular melanoma is likely to be important for reducing melanoma 
mortality.  
 
Clinical presentation of nodular melanoma 
 
There have been few studies that have compared the clinical presentation of NM 
versus SSM or the clinical presentation of early vs. late NM. 13 Compared with SSM, 
NMs have been commonly reported to be more symmetrical, of a single color, 
amelanotic, elevated, growing in diameter, and having a round border. Carli et al 14 found 
few differences between NM and SSM in terms of anatomic site, presence of atypical 
nevi, and number of common nevi. In our study, warning signs generally associated with 
SSM (although not as common) were also present in many patients with thin NM: 47% 
had brown pigmentation, 46% had a change in color and 22% had a change in size of 
their lesion. Very few patients with thin NM (1.4%) reported that the melanoma ‘just 
appeared’. Conversely, compared with SSM, patients with thick NM more commonly 
reported lumpy/raised appearance, paleness or no color, and a blister-like appearance, 
suggesting potential ulceration of the lesion. Likewise, lumpy/raised appearance was 
more common among thin NMs compared with SSMs. 
 
In this study, 61% of NMs were self-detected, 27% were detected by a partner, 
but only 11% were detected by the physician. In contrast, most studies have demonstrated 
that about 25% of superficial spreading melanoma is first discovered by a physician and 
that physician detection is uniformly associated with thinner disease. 18-25  Herein,  there 
was a trend toward more favorable NM being discovered by a physician (rather than self-
detected), suggesting the need to emphasize active surveillance for change in color or size 
(among other factors) for warning signs that may be associated with early NM or SSM.  
Since the US Institute of Medicine recommendations 26 alert physicians to suspicious 
signs in older persons, and because middle-aged and older patients who are most 
commonly diagnosed with NM11 also make frequent visits to their health care providers, 
physician-directed opportunistic screening might be suitable for detection of NM as well 
as for the more common SSM.  Given that many patients with thin NM reported a change 
in color before diagnosis, the importance of careful and regular skin self-examination 
should be promoted as well.  
 
Biologic features of nodular melanoma 
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Notably, older respondents (ages 60-79) were three times more likely than 
persons ages 40-59 to be diagnosed with thick NM and 12 times more likely than 
respondents ages 20-39. This finding could suggest that the biological features of 
melanoma may be different among middle-aged and older subjects, although it may also 
be due to other factors such as the elderly’s relative immunodeficiency, or that older 
individuals may have fewer social contacts and examine their own skin less often.   
 
According to recent studies, the rate of growth of primary cutaneous melanoma 
appears to differ based on histologic subtype. Liu et al recently estimated that NM grows 
at 4 times the rate of either SSM or lentigo maligna melanoma with an increase of nearly 
half a millimeter per month. 27 Unlike the current study, where there was no apparent 
association between self-reported “moliness” and NM thickness, Liu et al found an 
association between persons with few nevi and aggressive NM. 27  Earlier, using a 
melanoma kinetic index, Grob et found that aggressive tumor growth as reported by the 
patient rather than delay was responsible for thick melanoma.  28 Therefore, it is likely 
that a previously undetermined subset of NMs are fast-growing without a detectable pre-
clinical phase. Further epidemiologic and molecular studies should seek to determine 
ways of identifying persons at risk of faster-growing NM and explore the efficacy of 
more frequent and thorough screenings for those at greatest risk of fatal melanoma.   
 
Our study assumes that NM is a distinct biologic entity rather than a tumorigenic 
(vertical) growth phase applicable to any subtype of melanoma in which the horizontal 
growth phase (nontumorigenic microinvasive or in situ component) is not evident. While 
controversy persists regarding the validity of subtyping melanoma, recent evidence of 
divergent pathways of melanomagenesis according to anatomic location, sun exposure, 
nevus count, age of onset, and various mutations (e.g. B-RAF, c-Kit) suggest that distinct 
phenotypic and genotypic patterns of melanoma exist.  29-33 Though not universally 
accepted, the current widespread use of WHO classification of melanoma lends validity 
to the recognition of NM as a distinct biologic entity (WHO). 34 Congruent cancer 
registry data from Queensland and the SEER registry 10,12 indicate that the proportion of 
all invasive melanoma that are of the nodular subtype is nearly equal in these two 
countries, which supports the concept that World Health Organization classifications of 
melanoma subtype are similarly applied. As histologic subtype criteria undergo further 
refinement and reclassification, recognition of the nodular subtype accounting for 
disproportionate mortality and a significant fraction of all thick tumors is crucial to 
efforts to improve earlier diagnosis.  
 
Limitations 
 
Although early NM was associated with a physician visit in the three years prior 
to diagnosis, there is no evidence from this study that patients exhibited any signs or 
symptoms of NM at that visit, nor is there confirmation that a physician screen at this 
visit found a lesion appearing to be an early NM.  Moreover, the finding that thin NM 
was diagnosed in patients who had a physician screen in the three years before diagnosis 
may be unrelated to the physician examination and more a result of patients being aware 
of changing lesions. 
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Surprisingly, non-visible NM was thinner than visible NM.  Non-visible lesions 
were more likely to be detected by the partner or physician and partner or physician 
detection is more likely to be associated with thinner disease, however, a full explanation 
for thinner non-visible NM remains unclear.  
 
The coding of melanoma into the nodular and superficial spreading subtypes is 
completed internally by the Queensland Cancer Registry based on the information from 
state-wide  pathology laboratories.  Currently there has been no centralized histology 
review of these codes by independent experts.  A preliminary check has indicated that a 
proportion of nodular melanomas arising within SSMs have been coded as nodular 
melanomas (rather than invasive SSMs), but we were unable to quantify this precisely. 
 However, the fact that the proportion of nodular melanomas/all melanomas in 
Queensland has remained remarkably consistent for the past 20 years and that this rate is 
very close to those found in other population-based registries such as SEER should 
minimize concerns of differential reporting by pathology laboratories.  
 
Conclusions 
 
Our data highlight clinical and sociodemographic features (male gender and 
advanced age) associated with thicker NM. More importantly, this study  revealed that 
thick NM was  more common in individuals who did  not have a physician skin 
examination in the previous three years and among those who discovered their own 
lesions, rather than had them detected by a physician.  Well-established warning signs, 
heretofore associated with SSM (e.g. change in color and brown pigmentation), were also 
relatively common among patients diagnosed with thin NM. Enhanced public and 
professional education to raise awareness of the existence and warning signs associated 
with thinner NM may ultimately assist in improving earlier detection and treatment of 
this subtype. While we do not have definitive answers to the best methods for detecting 
earlier disease, this study raises the possibility that more frequent skin self-examinations 
by trained, high-risk individuals can contribute to the reduction of thick, rapidly growing 
melanoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 12
 
 13
Table 1: Ratios of geometric means for melanoma thickness (continuous variable 1) and 
selected variables (nodular melanomas only n=369) 
Variable Bivariate Multivariate 
Estimate2,3 95% 
Confidence 
interval 
Estimate 2,4 95% Confidence 
interval 
Sex   [χ2= 2.58, df=1, p=0.108] 5 [χ2=4.42, df=1, p=0.036] 5 
 Male (n=222) 1.13 [0.97, 1.31] 1.17 [1.01, 1.35] 
 Female (n=147) 1.00  1.00  
Age group   [χ2= 34.82, df=5, p<0.001] [χ2=27.27, df=5, p<0.001] 
 20 – 29 years (n=13) 0.98 [0.66, 1.45] 1.03 [0.70, 1.52] 
 30 – 39 years (n=39) 1.03 [0.79, 1.33] 1.14 [0.89, 1.47] 
 40 – 49 years (n=74) 1.00  1.00  
 50 – 59 years (n=90) 1.37 [1.12, 1.68] 1.43 [1.17, 1.75] 
 60 – 69 years (n=88) 1.37 [1.12, 1.68] 1.38 [1.12, 1.70] 
 70 – 75 years (n=65) 1.83 [1.47, 2.30] 1.79 [1.42, 2.26] 
Highest education  [χ2=14.34, df=2, p<0.001] [χ2=4.20, df=2, p=0.123] 
 Primary (n=35) 1.63 [1.26, 2.10] 1.31 [1.01, 1.69] 
 Years 7-10 (n=128) 1.13 [0.97, 1.32] 1.06 [0.91, 1.23] 
 Years 11-12 and upwards (n=205) 1.00  1.00  
Doctor-screen in previous 3 years   [χ2=7.43, df=1, p=0.006] [χ2=5.10, df=1, p=0.024] 
 Screened (n=103) 1.00  1.00  
 Not screened (n=266) 1.25 [1.06, 1.46] 1.20 [1.02, 1.41] 
Visibility of lesion     [χ2=4.57, df=1, p=0.033] [χ2=6.68, df=1, p=0.010] 
 Not visible (n=173) 1.00  1.00  
 Visible (n=196) 1.17 [1.01, 1.35] 1.20 [1.05, 1.38] 
Who first noticed the melanoma?  [χ2=5.88, df=2, p=0.053] [χ2=3.79, df=2, p=0.150] 
 Your partner (n=99) 1.12 [0.87, 1.44] 1.12 [0.85, 1.48] 
 Yourself (n=228) 1.28 [1.02, 1.61] 1.25 [0.96, 1.63] 
 Doctor (n=42) 1.00  1.00  
Method of detection     [χ2=3.39, df=1, p=0.066] [χ2=0.28, df=1, p=0.597] 
 By accident (n=325) 1.23 [0.99, 1.54] 1.07 [0.83, 1.39] 
 Deliberately (n=43) 1.00  1.00   
Self-screen in previous 3 years    [χ2=1.14, df=1, p=0.285] [χ2=0.13, df=1, p=0.723] 
 Screened (n=56) 1.00  1.00  
 Not screened (n=313) 1.11 [0.91, 1.36] 0.96 [0.79, 1.18] 
Skin reaction to summer sun     [χ2=0.12, df=1, p=0.728] [χ2=0.02, df=1, p=0.892] 
 Always / Usually burns  (n=191) 1.00  1.00  
 Sometimes / Never burns (n=178) 1.06 [0.92, 1.22] 1.01 [0.88, 1.16] 
Self reported “Moliness”   [χ2=1.99, df=1, p=0.159] [χ2=0.68, df=1, p=0.411] 
 Many / Some (n=153) 1.00  1.00  
 Few / None (n=215) 1.11 [0.96, 1.28] 1.06 [0.92, 1.21] 
1. Melanoma thickness was modeled on a log scale, and treated as a continuous variable. 
2. Estimates are the exponential of the relevant parameter estimate, and reflect the ratio of the geometric mean relative 
to the baseline. 
3. Unadjusted estimates 
4. Adjusted estimates are adjusted for all the other variables in the table 
5. Likelihood ratio statistics (Type III) for significance of variable. 
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Table 2 Adjusted odds ratios of thickest nodular melanoma (>4mm) compared with 
thinnest nodular melanoma (≤1mm) and intermediate nodular melanoma (>1 - 4mm)  
compared with thinnest nodular melanoma (≤1mm)  
 
Variable 1-4mm vs <1mm 4mm+ vs <1mm Overall significance 
Estimate
2,3 
95% 
Confidence 
interval 
Estimate
2,3 
95% 
Confidence 
interval 
      
Sex       [χ2=0.07, df=2, 
p=0.968] 
 Male (n=222) 0.91 [0.54, 1.55] 0.81 [0.36, 1.79]  
 Female (n=147) 1.00  1.00   
Age group     [χ2=14.85, df=4, 
p=0.005] 
 20 – 39 years (n=52) 1.05 [0.52, 2.11] 0.27 [0.05, 1.36]  
 40 – 59 years (n=164) 1.00  1.00   
 60 – 75 years (n=153) 2.47 [1.37, 4.47] 2.94 [1.33, 6.47]  
Highest education     [χ2=2.69, df=2, 
p=0.261] 
 Up to year 10 (n=163) 1.32 [0.76, 2.29] 1.65 [0.74, 3.71]  
 Years 11-12 and upwards (n=205) 1.00  1.00   
Doctor-screen in previous 3 years       [χ2=8.39, df=2, 
p=0.015] 
 Screened (n=103) 1.00  1.00   
 Not screened (n=266) 1.83 [1.07, 3.13] 3.75 [1.47, 9.59]  
Visibility of lesion         [χ2=7.51, df=2, 
p=0.023] 
 Not visible (n=173) 1.00  1.00   
 Visible (n=196) 1.57 [0.93, 2.67] 2.86 [1.25, 6.54]  
Who first noticed the melanoma?      [χ2=10.97, df=4, 
p=0.027] 
 Your partner (n=99) 2.26 [0.95, 5.37] 1.50 [0.31, 7.18]  
 Yourself (n=228) 1.55 [0.71, 3.37] 4.86 [1.21, 19.51]  
 Doctor (n=42) 1.00  1.00   
Method of detection         [χ2=3.55, df=2, 
p=0.169] 
 By accident (n=325) 1.42 [0.69, 2.96] 6.87 [1.28, 36.89]  
 Deliberately (n=43) 1.00  1.00   
Self-screen in previous 3 years        [χ2=4.82, df=2, 
p=0.090] 
 Screened (n=56) 1.00  1.00   
 Not screened (n=313) 1.99 [1.03, 3.85] 1.05 [0.39, 2.83]  
Skin reaction to summer sun         [χ2=2.39, df=2, 
p=0.303] 
 Always / Usually burns  (n=191) 1.00  1.00   
 Sometimes / Never burns (n=178) 1.22 [0.72, 2.05] 0.77 [0.34, 1.74]  
Self reported “Moliness”       [χ2=6.12, df=2, 
p=0.047] 
 Many / Some (n=153) 1.00  1.00   
 Few / None (n=215) 1.85 [1.10, 3.11] 1.32 [0.61, 2.86]  
1. Melanoma thickness was categorized into ≤1.00mm, >1mm - <4mm and > 4mm, and modeled using ordinal regression. 
2. Estimates are the exponential of the relevant parameter estimate, and reflect the odds relative to the baseline of <1mm 
3. All estimates adjusted for age and sex 
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Table 3: Percentage of non-doctor detected melanomas exhibiting  
selected clinical features and anatomic sites, by thickness (<2 mm and 2.01mm+) and histology (Nodular and 
SSM). 
 
 Thin (≤2.00mm) Thick (2.01mm+) 
 Nodular (%) 
[n=176] 
SSM (%)  
[n=1673]  
Nodular (%) 
[n=151] 
SSM (%) 
[n=81] 5 
Feature1,4     
Change in color  46.2 [38.9, 53.5] 64.2 [62.3, 66.2] 25.8  [18.7, 33.0] 25.9 [16.1, 35.7]  *** 
Change in size 22.1 [16.0, 28.2] 27.2 [25.4, 29.1] 21.2  [14.5, 27.9] 27.2 [17.2, 37.1] 
Irregular shape 10.4 [ 6.0, 14.9] 12.9 [11.5, 14.3] 2.0 [ 0.0, 4.3] 4.9 [0.1, 9.8] *** 
Irritation/itch 15.9 [10.6, 21.3] 12.3 [11.0, 13.7] 13.9 [ 8.2, 19.6] 21.0 [11.9, 30.1]
Lumpy/raised appearance 31.5 [24.7, 38.3] 19.1 [17.5, 20.7] 42.4 [34.3, 50.5] 37.0 [26.2, 47.9] *** 
‘‘Different from other spots’’ 9.2 [ 5.0, 13.4] 11.2 [9.9, 12.5] 9.3 [ 4.5, 14.0] 6.2 [0.8, 11.6] 
Bleeding/crusting/weeping 17.3 [11.8, 22.9] 4.6 [3.7, 5.4] 31.8  [24.2, 39.4] 13.6 [5.9, 21.3] *** 
‘‘It just appeared’’ 1.4 [ 0.0,  3.1] 3.1 [2.4, 3.8] 4.6 [ 1.2,  8.1] 1.2 [0.0, 3.7] 
Dry/scaly 1.6 [ 0.0,  3.4] 2.6 [2.0, 3.3] 4.0 [ 0.8,  7.2] 3.7 [0.0, 7.9] 
Blister-like 3.2 [ 0.6,  5.8] 1.4 [0.9, 1.8] 12.6  [ 7.2, 18.0] 4.9 [0.1, 9.8]  *** 
Pain 2.5 [ 0.2,  4.8] 1.3 [0.8, 1.8] 4.0 [ 0.8,  7.2] 4.9 [0.1, 9.8]  * 
Pigmentation2     
 Brown 47.4 [40.1, 54.7] 63.1 [61.1, 65.1] 27.2  [19.9, 34.4] 37.0 [26.2, 47.9] *** 
 Black 28.5 [21.9, 35.1] 32.4 [30.5, 34.4] 21.9 [15.1, 28.6] 18.5 [9.8, 27.2]  ** 
 Red/pink 19.7 [13.9, 25.5] 16.8 [15.3, 18.3] 39.1  [31.1, 47.1] 30.9 [20.5, 41.2] *** 
 Pale/white/no color 5.3 [ 2.0,  8.5] 3.8 [3.0, 4.6] 15.2  [ 9.4, 21.1] 11.1 [4.1, 18.2] *** 
 Gray/blue  3.2 [ 0.6,  5.7] 1.7 [1.2, 2.3] 3.3 [ 0.4,  6.2] 4.9 [0.1, 9.8] 
 Other 12.3 [ 7.5, 17.1] 14.5 [13.1, 16.0] 15.9 [ 9.9, 21.9] 16.0 [7.8, 24.3] 
     
Body site     
 Scalp and neck 11.6 [ 6.9, 16.3] 11.0 [9.7, 12.3] 23.2 [16.3, 30.1] 17.3 [8.8, 25.8] *** 
 Upper extremities 18.5 [12.8, 24.2] 20.4 [18.7, 22.0] 19.2 [12.8, 25.7] 23.5 [14.0, 33.0] 
 Lower extremities 29.2 [22.6, 35.9] 28.2 [26.3, 30.0] 27.8 [20.5, 35.1] 18.5 [9.8, 27.2] 
 Back of trunk 34.2 [27.2, 41.1] 32.0 [30.1, 33.9] 23.8 [16.9, 30.8] 29.6 [19.4, 39.9] 
 Front of trunk 6.5 [ 2.9, 10.1] 8.4 [7.3, 9.6] 6.0 [ 2.1,  9.8] 11.1 [4.1, 18.2] 
 
Notes: 
1. “On the [date first believed something was wrong] what was it about the spot that made you or someone else believe 
something might be wrong? 
2. “What colour (or colours) was the spot?” 
3. Percentages and 95% confidence intervals weighted to account for undersampling of thinner melanomas. 
4. Multiple responses possible. 
5. Significance of overall differences between groups (chi-squared test) : *** p<0.001 ; ** p<0.01 ; * p<0.05 
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Nearly 60% of nodular melanomas were diagnosed ≤2.0 mm and the report of a 
physician skin cancer examination was more common in these patients. Along with 
earlier studies, it appears that a significant subset of nodular melanomas can be 
detected relatively early. 
  
 
